AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
Shares of AstraZeneca traded 3% lower in after-hours trading on Friday after the drugmaker said a large late-stage breast cancer study of Etcamah missed its main goal, denting hopes of a broader first-line use for one of its most closely watched oncology assets.What The Trial ShowedThe trial SERENA…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.